Evolus (NASDAQ:EOLS), a company dedicated to aesthetic medicine, today announced that Health Canada has granted approval of DWP-450 (prabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows seen at maximum frown) in adult patients under 65 years of age. The first marketing approval for Evolus’ …
Evolus (NASDAQ:EOLS), a company dedicated to aesthetic medicine, today announced that Health Canada has granted approval of DWP-450 (prabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows seen at maximum frown) in adult patients under 65 years of age. The first marketing approval for Evolus’ DWP-450 product candidate represents a major milestone achievement for the company.
As quoted in the press release:
Evolus will market DWP-450 in Canada through its partner Clarion Medical Technologies, Inc, a leading Canadian provider of medical and aesthetic equipment and consumables to hospitals, aesthetic clinics and private medical practices.
David Moatazedi, President and Chief Executive Officer of Evolus, commented, “The marketing approval of DWP-450 in Canada represents a key achievement for Evolus in our regulatory efforts as it is the first approval worldwide of our neurotoxin, and ahead of our guided timeline in Canada. DWP-450 offers a significant and valuable competitive opportunity given the meaningful gap between the neurotoxin market leader and other available products, and we look forward to our partner providing DWP-450 to physicians and consumers in Canada in the first half of 2019.”
Rui Avelar, MD, Chief Medical Officer and Head of R&D of Evolus, added, “This marketing approval positions Evolus with a competitive advantage as the first known 900 kda molecule approved since Botox®. The approval from Health Canada is based on the results from our clinical program that included our EV-001 and EV-002 pivotal phase III studies in the United States and supported by our EVB-003 pivotal Phase III study in the European Union and Canada.”